In Vitro and in Silico Evaluation of the Potential for Neuroprotection of RhodioLife, a Rhodiola Rosea Roots Extract

Jose M Zubeldia, Aaron Hernandez-Santana, Miguel Jimenez del Rio, Veronica Perez-Lopez


Rhodiola rosea, an adaptogen plant from cold regions, has been previously proposed for alleviating dementia and other neurodegenerative diseases. The goal of our study was to evaluate if our proprietary extract (RhodioLife) was able to elicit biological responses related to neuroprotection in neuronal cultures. NS20Y cells were cultured according to procedures and increasing concentrations of RhodioLife were added to the media. Viability at 24h using Presto BlueTM showed no statistically significant differences at those concentrations (0-50 ppm). Quantitative real-time RT-PCR analysis (G-coupled protein receptor [GCPR] array) showed statistically significant (p<0.05) upregulation of 3 genes: calcitonin receptor-like (CALCRL), cyclin-dependent kinase inhibitor 1A (CDKN1A), and lysophosphatidic acid receptor 2 (LPAR2) (4, 3 and 2-fold respectively).  In silico evaluation of the bioactives contained in RhodioLife ( revealed that Salidroside, Rosarin, Rosavin, Rosiridin, Cinnamyl alcohol and p-Tyrosol all had 1 or no violations of the Lipinski´s rule of five, suggesting favorable pharmacokinetics. The predicted G-coupled protein receptor bioactivity was greatest for Rosarin (0.39) and Salidroside (0.35). We conclude that RhodioLife contained substances which had relevant biological activity and molecular properties suggesting a role in neuroprotection.   Studies in suitable animal models are recommended.

Full Text:




  • There are currently no refbacks.

Copyright (c) 2013 Jose M Zubeldia, Aaron Hernandez-Santana, Miguel Jimenez del Rio, Veronica Perez-Lopez

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

Journal of Food Studies (ISSN 2166-1073)

Copyright © Macrothink Institute  

To make sure that you can receive messages from us, please add the '' domain to your e-mail 'safe list'. If you do not receive e-mail in your 'inbox', check your 'bulk mail' or 'junk mail' folders. If you have any questions, please contact: